{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T20:39:14Z","timestamp":1759178354054},"reference-count":23,"publisher":"The Society for Free Radical Research Japan","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Biochem. Nutr."],"published-print":{"date-parts":[[2022]]},"DOI":"10.3164\/jcbn.22-7","type":"journal-article","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T22:09:56Z","timestamp":1652738996000},"page":"158-164","source":"Crossref","is-referenced-by-count":3,"title":["Insulin dose reduction in dapagliflozin combination therapy for type 1 diabetes mellitus: the RISING-STAR study"],"prefix":"10.3164","volume":"71","author":[{"given":"Masahide","family":"Hamaguchi","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Yoshimura","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanako","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Japanese Red Cross Kyoto Daiichi Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Goji","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Division of Metabolism, Nephrology and Rheumatology, Japanese Red Cross Kyoto Daini Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiyo","family":"Ishii","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Otsu City Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Matsushita Memorial Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuteru","family":"Mitsuhashi","sequence":"additional","affiliation":[{"name":"Department of Diabetes Internal Medicine, Fukuchiyama City Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyuki","family":"Kitagawa","sequence":"additional","affiliation":[{"name":"Department of Diabetology, Kameoka Municipal Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuro","family":"Okamura","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saori","family":"Majima","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Senmaru","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emi","family":"Ushigome","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Nakanishi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mai","family":"Asano","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiaki","family":"Fukui","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the RISING-STAR study group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1739","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: <i>Standards of Medical Care in Diabetes-2019<\/i>. Diabetes Care 2019; 42(Suppl 1): S90\u2013S102.","DOI":"10.2337\/dc19-S009"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Davidson PC, Hebblewhite HR, Steed RD, Bode BW. Analysis of guidelines for basal-bolus insulin dosing: basal insulin, correction factor, and carbohydrate-to-insulin ratio. Endocr Pract 2008; 14: 1095\u20131101.","DOI":"10.4158\/EP.14.9.1095"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Kuroda A, Kaneto H, Yasuda T, et al. Basal insulin requirement is \u223c30% of the total daily insulin dose in type 1 diabetic patients who use the insulin pump. Diabetes Care 2011; 34: 1089\u20131090.","DOI":"10.2337\/dc10-2149"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 King AB. How much do I give? Reevaluation of insulin dosing estimation formulas using continuous glucose monitoring. Endocr Pract 2010; 16: 428\u2013432.","DOI":"10.4158\/EP09308.OR"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Edqvist J, Rawshani A, Adiels M, et al. BMI, mortality, and cardiovascular outcomes in type 1 diabetes: findings against an obesity paradox. Diabetes Care 2019; 42: 1297\u20131304.","DOI":"10.2337\/dc18-1446"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Tascini G., Berioli MG, Cerquiglini L, et al. Carbohydrate counting in children and adolescents with type 1 diabetes. Nutrients 2018; 10: 109.","DOI":"10.3390\/nu10010109"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Boeder S, Edelman SV. Sodium-glucose co-transporter inhibitors as adjunctive treatment to insulin in type 1 diabetes: a review of randomized controlled trials. Diabetes Obes Metab 2019; 21(Suppl 2): 62\u201377.","DOI":"10.1111\/dom.13749"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Mathieu C, Dandona P, Gillard P, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 24-week results from a randomized controlled trial. Diabetes Care 2018; 41: 1938\u20131946.","DOI":"10.2337\/dc18-0623"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Henry RR, Thakkar P, Tong C, Polidori D, Alba M. Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care 2015; 38: 2258\u20132265.","DOI":"10.2337\/dc15-1730"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Dandona P.Mathieu C, Phillip M, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 2017; 5: 864\u2013876.","DOI":"10.1016\/S2213-8587(17)30308-X"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Pieber TR, Famulla S, Eilbracht J, et al. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1). Diabetes Obes Metab 2015; 17: 928\u2013935.","DOI":"10.1111\/dom.12494"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Rosenstock J, Marquard J, Laffel LM, et al. Empagliflozin as adjunctive to insulin therapyin type 1 diabetes: the EASE trials. Diabetes Care 2018; 41: 2560\u20132569.","DOI":"10.2337\/dc18-1749"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Buse JB, Garg SK, Rosenstock J, et al. Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the North American in Tandem1 study. Diabetes Care 2018; 41: 1970\u20131980.","DOI":"10.2337\/dc18-0343"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Wanner C, Heerspink HJL, Zinman B, et al. Empagliflozin and kidney function decline in patients with type 2 diabetes: a slope analysis from the EMPA-REG OUTCOME trial. J Am Soc Nephrol 2018; 29: 2755\u20132769.","DOI":"10.1681\/ASN.2018010103"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Kovatchev B, Cobelli C. Glucose variability: timing, risk analysis, and relationship to hypoglycemia in diabetes. Diabetes Care 2016; 39: 502\u2013510.","DOI":"10.2337\/dc15-2035"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Lehecka KE, Renukuntla VS, Heptulla RA. Insight into hypoglycemia in pediatric type 1 diabetes mellitus. Int J Pediatr Endocrinol 2012; 2012: 19.","DOI":"10.1186\/1687-9856-2012-19"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Hamaguchi M, Hashimoto Y, Tanaka T, et al. Multicenter, open-label, 2-arm, pilot trial for safe reduction of basal insulin dose combined with SGLT2 inhibitor in type 1 diabetes mellitus: study protocol for a RISING-STAR trial. Clin Med Insights Endocrinol Diabetes 2021; 14: 11795514211040539.","DOI":"10.1177\/11795514211040539"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Chen J, Fan F, Wang JY, et al. The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis. Sci Rep 2017; 7: 44128.","DOI":"10.1038\/srep44128"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Musso G, Gambino R, Cassader M, Paschetta E. Efficacy and safety of dual SGLT 1\/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 2019; 365: l1328.","DOI":"10.1136\/bmj.l1328"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Urakami T, Kuwabara R, Habu M, Okuno M, Suzuki J, Takahashi S. Efficacy and safety of switching to insulin glulisine from other rapid-acting insulin analogs in children with type 1 diabetes. J Diabetes Investig 2015; 6: 87\u201390.","DOI":"10.1111\/jdi.12253"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 King AB, Kuroda A, Matsuhisa M, Hobbs T. A review of insulin-dosing formulas for continuous subcutaneous insulin infusion (CSII) for adults with type 1 diabetes. Curr Diab Rep 2016; 16: 83.","DOI":"10.1007\/s11892-016-0772-0"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Henry RR, Dandona P, Pettus J, Mudaliar S, Xu J, Hansen L. Dapagliflozin in patients with type 1 diabetes: a post hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting \u03b2-hydroxybutyrate levels in a phase IIa pilot study. Diabetes Obes Metab 2017; 19: 814\u2013821.","DOI":"10.1111\/dom.12882"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Garg SK, Peters AL, Buse JB, Danne T. Strategy for mitigating DKA risk in patients with type 1 diabetes on adjunctive treatment with SGLT inhibitors: a STICH protocol. Diabetes Technol Therap 2018; 20: 571\u2013575.","DOI":"10.1089\/dia.2018.0246"}],"container-title":["Journal of Clinical Biochemistry and Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jcbn\/71\/2\/71_22-7\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T04:56:41Z","timestamp":1662181001000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jcbn\/71\/2\/71_22-7\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.3164\/jcbn.22-7","relation":{},"ISSN":["0912-0009","1880-5086"],"issn-type":[{"type":"print","value":"0912-0009"},{"type":"electronic","value":"1880-5086"}],"subject":[],"published":{"date-parts":[[2022]]},"article-number":"22-7"}}